DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. [electronic resource]
Producer: 20201112Description: 406-414 p. digitalISSN:- 1532-6535
- Adolescent
- Adult
- Area Under Curve
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Half-Life
- Humans
- Leukocytes, Mononuclear -- drug effects
- Male
- Metabolic Clearance Rate
- Middle Aged
- Phosphorylation -- drug effects
- Receptor-Interacting Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.